InspireMD to Announce Second Quarter 2025 Financial Results
Rhea-AI Summary
InspireMD (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system, will release its Q2 2025 financial results on Tuesday, August 5, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and recent highlights.
Investors can access the earnings call by dialing 1-800-579-2543 (domestic) or 1-785-424-1789 (international). A webcast will be available on InspireMD's website, and a replay will be archived for later viewing.
Positive
- None.
Negative
- None.
News Market Reaction – NSPR
On the day this news was published, NSPR declined 0.28%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $216K from the company's valuation, bringing the market cap to $77M at that time.
Data tracked by StockTitan Argus on the day of publication.
MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD’s website or by registering below. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on InspireMD’s website.
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1723041&tp_key=b02c396fff
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR.
We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Investor Contact:
Webb Campbell
Gilmartin Group LLC
Webb@gilmartinir.com
investor-relations@inspiremd.com
FAQ
When will InspireMD (NSPR) report Q2 2025 earnings?
How can I listen to InspireMD's Q2 2025 earnings call?
What does InspireMD (NSPR) manufacture?
Will there be a replay of InspireMD's Q2 2025 earnings call?
